AxoGen (AXGN) Expected to Announce Earnings on Tuesday

Key Points

• AxoGen is expected to announce its Q2 2025 earnings on August 5th, with analysts predicting earnings of $0.06 per share and revenue of $52.61 million.
• Shares of AxoGen saw a 1.3% increase recently, reaching $13.16, with a market capitalization of approximately $599.49 million.
• Recent activities from institutional investors indicate significant trading interest, with several hedge funds increasing their stakes in the company, bringing institutional ownership to 80.29%.

AxoGen (NASDAQ:AXGN - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $52.61 million for the quarter.

AxoGen Stock Performance

AXGN traded up $0.06 during trading hours on Friday, hitting $13.15. The company's stock had a trading volume of 176,947 shares, compared to its average volume of 693,277. AxoGen has a fifty-two week low of $7.34 and a fifty-two week high of $21.00. The company has a current ratio of 4.28, a quick ratio of 2.65 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $599.03 million, a PE ratio of -87.66 and a beta of 1.04. The company has a 50-day simple moving average of $11.19 and a 200 day simple moving average of $14.93.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group lowered their target price on AxoGen from $26.00 to $24.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $24.50.

Insider Transactions at AxoGen

In other news, Director Joseph A. Tyndall sold 20,062 shares of the firm's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $11.20, for a total transaction of $224,694.40. Following the completion of the sale, the director directly owned 15,345 shares of the company's stock, valued at $171,864. This trade represents a 56.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 2.78% of the company's stock.

Institutional Investors Weigh In On AxoGen

Large investors have recently modified their holdings of the stock. Jones Financial Companies Lllp boosted its stake in shares of AxoGen by 104,810.0% during the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider's stock worth $194,000 after acquiring an additional 10,481 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of AxoGen by 45.3% during the 1st quarter. AQR Capital Management LLC now owns 23,917 shares of the medical equipment provider's stock worth $442,000 after acquiring an additional 7,453 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of AxoGen by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider's stock worth $466,000 after acquiring an additional 1,057 shares in the last quarter. Finally, Royal Bank of Canada boosted its stake in shares of AxoGen by 14.2% during the 1st quarter. Royal Bank of Canada now owns 38,043 shares of the medical equipment provider's stock worth $704,000 after acquiring an additional 4,723 shares in the last quarter. 80.29% of the stock is owned by institutional investors.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.